血管緊張素1-7(Ang1-7)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)
Multiplex Assay Kit for Angiotensin 1-7 (Ang1-7) ,etc. by FLIA (Flow Luminescence Immunoassay)
（注：?jiǎn)未位鞙y(cè)多因子不超過(guò)8個(gè)指標(biāo) ）
- 編號(hào)ULMS085Hu
- 物種Homo sapiens (Human，人) 相同的名稱(chēng)，不同的物種。
- 實(shí)驗(yàn)方法競(jìng)爭(zhēng)抑制
- 反應(yīng)時(shí)長(zhǎng)1.5h
- 檢測(cè)范圍0.98-1000pg/mL
- 靈敏度最小可檢測(cè)劑量小于等于0.327 pg/mL.
- 樣本類(lèi)型Serum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids
- 下載 英文說(shuō)明書(shū) 中文說(shuō)明書(shū)
- 規(guī)格 8指標(biāo)數(shù) 7指標(biāo)數(shù) 6指標(biāo)數(shù) 5指標(biāo)數(shù) 4指標(biāo)數(shù) 3指標(biāo)數(shù) 2指標(biāo)數(shù)1指標(biāo)數(shù)
- 價(jià)格 ¥ 1385 ¥ 1439 ¥ 1518 ¥ 1625 ¥ 1732 ¥ 1891 ¥ 2131 ¥ 2664 添加到價(jià)格計(jì)算器 計(jì)算器
- 欲了解實(shí)際交易價(jià)格和更多情況，請(qǐng)與當(dāng)?shù)亟?jīng)銷(xiāo)商聯(lián)系!
-
產(chǎn)品包裝(模擬)
-
產(chǎn)品包裝(模擬)
-
通過(guò)ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
特異性
本試劑盒用于檢測(cè)血管緊張素1-7(Ang1-7)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)，經(jīng)檢測(cè)與其它相似物質(zhì)無(wú)明顯交叉反應(yīng)。
由于受到技術(shù)及樣本來(lái)源的限制，不可能完成對(duì)所有相關(guān)或相似物質(zhì)交叉反應(yīng)檢測(cè)，因此本試劑盒有可能與未經(jīng)檢測(cè)的其它物質(zhì)有交叉反應(yīng)。
回收率
分別于定值血清及血漿樣本中加入一定量的血管緊張素1-7(Ang1-7)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)（加標(biāo)樣品），重復(fù)測(cè)定并計(jì)算其均值，回收率為測(cè)定值與理論值的比率。
| 樣本 | 回收率范圍(%) | 平均回收率(%) |
| serum(n=5) | 93-102 | 98 |
| EDTA plasma(n=5) | 84-99 | 93 |
| heparin plasma(n=5) | 92-101 | 95 |
精密度
精密度用樣品測(cè)定值的變異系數(shù)CV表示。CV(%) = SD/mean×100
批內(nèi)差：取同批次試劑盒對(duì)低、中、高值定值樣本進(jìn)行定量檢測(cè),每份樣本連續(xù)測(cè)定20 次，分別計(jì)算不同濃度樣本的平均值及SD值。
批間差：選取3個(gè)不同批次的試劑盒分別對(duì)低、中、高值定值樣本進(jìn)行定量測(cè)定，每個(gè)樣本使用同一試劑盒重復(fù)測(cè)定8次，分別計(jì)算不同濃度樣本的平均值及SD值。
批內(nèi)差： CV<10%
批間差： CV<12%
線性
在定值血清及血漿樣本內(nèi)加入適量的血管緊張素1-7(Ang1-7)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)，并倍比稀釋成1:2，1:4，1:8，1:16的待測(cè)樣本，線性范圍即為稀釋后樣本中血管緊張素1-7(Ang1-7)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)含量的測(cè)定值與理論值的比率。
| 樣本 | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 86-94% | 93-101% | 84-101% | 80-89% |
| EDTA plasma(n=5) | 78-99% | 88-99% | 88-102% | 93-102% |
| heparin plasma(n=5) | 82-94% | 85-96% | 94-104% | 92-99% |
穩(wěn)定性
經(jīng)測(cè)定，試劑盒在有效期內(nèi)按推薦溫度保存，其活性降低率小于5%。
為減小外部因素對(duì)試劑盒破壞前后檢測(cè)值的影響，實(shí)驗(yàn)室的環(huán)境條件需盡量保持一致，尤其是實(shí)驗(yàn)室內(nèi)溫度、濕度及溫育條件。其次由同一實(shí)驗(yàn)員來(lái)進(jìn)行操作可減少人為誤差。
實(shí)驗(yàn)流程
1. 實(shí)驗(yàn)前標(biāo)準(zhǔn)品、試劑及樣本準(zhǔn)備；
2. 加樣（標(biāo)準(zhǔn)品、樣本、磁珠、檢測(cè)溶液A）標(biāo)準(zhǔn)品或樣本50μL及磁珠10μL，加檢測(cè)溶液A50μL，
37°C酶標(biāo)板振蕩器孵育60分鐘；
3. 磁吸洗板3次；
4. 加檢測(cè)溶液B100μL，37°C振動(dòng)孵育30分鐘；
5. 磁吸洗板3次；
6. 加鞘液100μL，旋渦震蕩2分鐘后讀數(shù)。
實(shí)驗(yàn)原理
將血管緊張素1-7(Ang1-7)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)抗體包被于磁珠，制成固相載體，向微孔中分別加入標(biāo)準(zhǔn)品或標(biāo)本以及磁珠、標(biāo)記VEGFA，標(biāo)記的血管緊張素1-7(Ang1-7)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)和未標(biāo)記的血管緊張素1-7(Ang1-7)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)與連接于固相載體上的抗體競(jìng)爭(zhēng)結(jié)合，然后將未結(jié)合物洗凈后，加入PE標(biāo)記的親和素，再次徹底洗滌后即可上機(jī)讀數(shù)。MFI值和樣品中的血管緊張素1-7(Ang1-7)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)呈負(fù)相關(guān)。
贈(zèng)品
增值服務(wù)
相關(guān)產(chǎn)品
| 編號(hào) | 適用物種：Homo sapiens (Human，人) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| UCPS085Hu21 | 血管緊張素1-7(Ang1-7)卵白蛋白偶聯(lián)物 | Immunogen; SDS-PAGE; WB. |
| UPAS085Hu01 | 血管緊張素1-7(Ang1-7)多克隆抗體 | IHC |
| ULAS085Hu71 | 血管緊張素1-7(Ang1-7)多克隆抗體(生物素標(biāo)記) | WB; IHC; ICC. |
| UCES085Hu | 血管緊張素1-7(Ang1-7)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| UCCS085Hu | 血管緊張素1-7(Ang1-7)檢測(cè)試劑盒(化學(xué)發(fā)光免疫分析法) | Chemiluminescent immunoassay for Antigen Detection. |
| ULMS085Hu | 血管緊張素1-7(Ang1-7)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
| UKSS085Hu11 | 血管緊張素1-7(Ang1-7)檢測(cè)試劑盒DIY材料(酶聯(lián)免疫吸附試驗(yàn)法) | Main materials for "Do It (ELISA Kit) Yourself". |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| J Stroke Cerebrovasc Dis | Improvement of Plasma Biomarkers after Switching Stroke Patients from Other Angiotensin II Type I Receptor Blockers to Olmesartan [PubMed: 25891757] |
| Cellular Physiology and Biochemistry | Angiotensin-(1-7) in Paraventricular Nucleus Contributes to the Enhanced Cardiac Sympathetic Afferent Reflex and Sympathetic Activity in Chronic Heart Failure Rats [pubmed:28848201] |
| Frontiers in Physiology | Hydrogen Sulfide Attenuates Atherosclerosis in a Partially Ligated Carotid Artery Mouse model via Regulating Angiotensin Converting Enzyme 2 Expression [pubmed:29066981] |
| Molecular Medicine Reports | The ACE2-Ang (1-7)-Mas receptor axis attenuates cardiac remodeling and fibrosis in post-myocardial infarction. [pubmed:28656296] |
| Journal of Clinical Pharmacy and Therapeutics | Relationship between genetic variants of ACE2 gene and circulating levels of ACE2 and its metabolites. [pubmed:28895159] |
| Molecular Medicine Reports | Effects of IQP, VEP and Spirulina platensis hydrolysates on the local kidney renin angiotensin system in spontaneously hypertensive rats [pubmed:28944898] |
| Open Journal of Endocrine and Metabolic Diseases Paper Submission | A Study of the Correlation between Angiotensin (1-7) and the Histopathological Changes in the Penises of Experimentally Diabetic Rats [2-1980272_83198.htm] |
| Journal of the American Society of Hypertension | Mesenchymal stem cell–derived microvesicles alleviate pulmonary arterial hypertension by regulating renin-angiotensin system [Pubmed:29752040] |
| Innate?Immunity? | Lipoxin A attenuates LPS-induced acute lung injury via activation of the ACE2-Ang-(1-7)-Mas axis [Pubmed:29969931] |
| Evidence-based?Complementary and Alternative?Medicine? | Acute Biochemical, Cardiovascular, and Autonomic Response to Hyperbaric (4 atm) Exposure in Healthy Subjects [Pubmed:29977313] |
| European Journal of Obstetrics & Gynecology and Reproductive Biology | The impact of ovulation inducing drugs on carcinogenesis [] |
| European Journal of Obstetrics & Gynecology and Reproductive Biology | Changes of angiotensin II (1–8) and angiotensin (1–7) levels in early and late-onset preeclampsia [] |
| Journals of Gerontology Series A-Biological Sciences and Medical Sciences | Therapeutic Delivery of Ang (1-7) Via Genetically Modified Probiotic: A Dosing Study. [Pubmed: 31586210] |
| journal of the european academy of dermatology and venereology | Significance of the angiotensin I/angiotensin II/angiotensin‐(1‐7) axis in the pathogenesis of systemic sclerosis [Pubmed: 31746507] |
| Medicine | Alteration and association between serum ACE2/angiotensin (1-7)/Mas axis and oxidative stress in chronic kidney disease: A pilot study [Pubmed: 32756181] |
| Dikkat Eksikli?i Hiperaktivite Bozuklu?u Tan?s? Olan Anjiyotensin I, II, III, Alamandin peptid, Anjiyotensin D?nü?türücü Enzim (ACE), NADPH Oksidaz Enzim Serum?… [] | |
| Amino Acids | Angiotensin-(1¨C7) attenuates collagen-induced arthritis via inhibiting oxidative stress in rats [33398523] |
| Autoimmunity | The prevalence and role of functional autoantibodies to angiotensin-converting-enzyme-2 in patients with systemic sclerosis [33910447] |
| researchsquare | Ang-(1-7) Protects Skeletal Muscle Function in Aged Mice [] |
| Peptides | Angiotensin-(1-7) protects against sepsis-associated left ventricular dysfunction induced by lipopolysaccharide [34298021] |
| BMC Musculoskeletal Disorders | Ang-(1–7) protects skeletal muscle function in aged mice [34548056] |
| J Cardiovasc Pharmacol | Resveratrol Confers Protection Against Ischemia/Reperfusion Injury by Increase of Angiotensin (1-7) Expression in a Rat Model of Myocardial Hypertrophy [34232225] |
